My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice - Episode 4
Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM
The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.
Video Player is loading.
Video content above is prompted by the following:
- How has the treatment landscape evolved for patients with r/r MM, post 1-3 lines of therapy, especially in the setting of increasing use of anti-CD38 monoclonal antibodies in the newly diagnosed or early relapse space?
- What are currently available treatment options?
- What is the utility of Selinexor in the post anti-CD38-monoclonal antibody setting?
Related Content:
